After years of controversy over access to trial data, GlaxoSmithKline announced today that it will make patient-level data from its drug trials available to researchers. “This doesn’t sound like transparency to me,” said MIA blogger Carl Elliott, a professor at the Center for Bioethics at the University of Minnesota, “It sounds like a PR tactic. If I suspect that researchers on a GSK-funded trial have rigged the design or cooked the data, is this ‘independent panel of experts’ going to give me access?”
Glaxo Peels Back Curtain On Drug Data (Pharmalot)
Glaxo Opens Door to Data on Research (NY Times)
